バイオ医薬品市場レポート：2024-2034
Biologics Market Report 2024-2034
レポート詳細
バイオ医薬品市場レポート 2024-2034 ：この調査レポートは、業界とその基礎となるダイナミクスをより良く理解することを望むなら、新たな収益ポケットを目指す大手企業にとって非常に... もっと見る
※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。
サマリー
レポート詳細
バイオ医薬品市場レポート 2024-2034：この調査レポートは、業界とその基礎となるダイナミクスをより良く理解することを望むなら、新たな収益ポケットを目指す大手企業にとって非常に貴重なものとなるでしょう。異業種への進出や新地域での既存事業の拡大を目指す企業にも有用です。
再生医療と細胞生物学の進歩が市場成長を牽引
細胞生物学と再生医療の進歩は、心血管疾患、腫瘍、代謝疾患、筋骨格系疾患など、様々な疾患をターゲットとする幹細胞ベースの治療法の強固な基盤を築き、市場の成長を牽引している。このような画期的な治療法は、複雑な医学的課題に対処するための革新的な戦略の可能性を世界中の患者に提供している。この分野での継続的な探求と革新は、衰弱させる病気を効果的に管理し、場合によっては取り除くことができる未来を切り開き、さらなるマイルストーンを達成する態勢を整えている。エディタス・メディシン（Editas Medicine）、CRISPRセラピューティクス（CRISPR Therapeutics）、インテリア・セラピューティクス（Intellia Therapeutics）といった企業は、CRISPR-Cas9遺伝子編集技術を遺伝子治療や再生医療への応用の可能性に活用し、遺伝子障害を分子レベルで是正することを目指している。さらに、ベリセルのFDA承認のMACI（マトリックス誘導自己軟骨細胞移植）は、患者自身の細胞を利用して膝軟骨の欠損を修復する。
バイオ医薬品の特許切れがもたらす課題
バイオ医薬品の初期世代の特許が切れ、バイオシミラーが間もなく市場に参入するため、競争激化への道が開かれつつある。バイオシミラー医薬品は、すでに承認されている生物学的製剤の品質を再現するように設計されており、医療費削減を目指す政府によって世界的に勢いを増している。特に、インドの中央医薬品標準管理機構（CDSCO）は、インドのバイオシミラー業界を後押しするために「類似バイオ医薬品ガイドライン」を導入した。バイオテクノロジーにおけるバイオ医薬品分野は急速に発展しており、その60％以上が糖尿病、自己免疫疾患、癌の治療に特化しているため、コストが高騰している。世界保健機関（WHO）は、このような高価格がもたらす障壁を認識し、ジェネリック医薬品メーカーが特許の期限切れに合わせてバイオシミラーを製造する機会を強調している。ジェネリック医薬品メーカーは、特許切れのバイオ医薬品を積極的に探しており、2021年から2025年の間に230の医薬品の特許が切れることになっている。2024年に特許が切れるバイオ医薬品としては、PERJETA（ペルツズマブ）、VYROLOGIX（レロンリマブ）、STELARA（ウステキヌマブ）などが注目される。Center for Biosimilarsは、現在バイオ医薬品ががん領域の医薬品業界の半分を占めているが、2024年までに20品目近いがん領域のバイオ医薬品の特許が切れることで、がん治療におけるバイオシミラーの使用が増加し、全体的なコスト削減に貢献する可能性があると指摘している。
市場調査レポートを購入する前にすべき質問とは？
- バイオ医薬品市場はどのように進化しているのか？
- バイオ医薬品市場の推進要因と阻害要因は何か？
- バイオ医薬品の各サブ市場セグメントは予測期間中にどのように成長し、2034年にはどれくらいの売上を占めるようになるのか？
- 各バイオ医薬品サブマーケットの市場シェアは2024年から2034年にかけてどのように推移するのか？
- 2024年から2034年までの市場全体の主な牽引役は何か？
- 主要なバイオ医薬品市場はマクロ経済の動きに大枠で追随するのか、それとも個々の国内市場が他を凌駕するのか？
- 2034年までに各国市場のシェアはどう変化し、2034年に市場をリードするのはどの地域か？
- 主要プレーヤーは誰で、予測期間中の見通しは？
- これらの主要企業のバイオ医薬品プロジェクトは何か？
- 2024年から2034年の間に、業界はどのように発展するのか？現在および今後10年間に実施されるバイオ医薬品プロジェクトにはどのような意味があるのか？
- バイオ医薬品市場をさらに拡大するために、製品の商業化の必要性は高まっているのか？
- バイオ医薬品市場はどこに向かい、どのようにすれば市場の最前線に立てるのか？
- 新製品やサービスラインへの最適な投資オプションは何か？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？
このことがバイオ医薬品市場に現在、そして今後10年間にどのような影響を与えるかを知る必要がある：
- 312ページにわたる本レポートでは、127の表と213の図表を掲載しています。
- 本レポートは、業界の主要な儲かる分野にスポットを当てているため、今すぐターゲットを絞ることができます。
- 世界、地域、国の売上と成長に関する詳細な分析が含まれています。
- 競合他社が成功した主なトレンド、変化、収益予測をハイライトしています。
本レポートは、バイオ医薬品市場が今後10年間にどのように発展するか、またCOVID-19の景気後退と好転の変動に合わせてどのように発展するかをお伝えします。この市場は、過去10年間のどの時点よりも今が重要である。
2034年までの予測やその他の分析から、商業的な展望が明らかになる
- 2034年までの収益予測に加え、直近の実績、成長率、市場シェアを提供します。
- ビジネスの展望と展開に関する独自の分析をご覧いただけます。
- 定性的分析（市場ダイナミクス、促進要因、機会、阻害要因、課題を含む）、コスト構造、バイオ医薬品価格上昇の影響、最近の動向をご覧いただけます。
本レポートには、COVID-19が業界と貴社にどのような影響を与えるかについてのデータ分析と貴重な洞察が含まれている。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じている。
レポート対象セグメント
製品見通し
・ モノクローナル抗体
- ヒト
- ヒト化抗体
- キメラ
- マウス
- ワクチン
・ 組み換えタンパク質
・ 再生医療
・ 組織工学製品
- 細胞治療
- 遺伝子治療
・ その他
用途
- 腫瘍学
- 感染症
- 自己免疫疾患
- 血液疾患
- 心血管疾患
- その他
製造タイプ
- アウトソース
- インハウス
エンドユーザー
- 病院
- 専門センター
- その他
世界市場全体と各分野の収益予測に加え、5つの地域と22の主要国市場の収益予測も掲載している：
北米
- アメリカ
- カナダ
欧州
- ドイツ
- 英国
- フランス
- スペイン
- イタリア
- ロシア
- その他の欧州
アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- その他のアジア太平洋地域
ラテンアメリカ
- ブラジル
- メキシコ
- アルゼンチン
- その他のラテンアメリカ
MEA
- GCC
- 南アフリカ
- その他のMEA
.png)
また、2024年から2034年までのバイオ医薬品市場における主要企業のプロファイルも掲載している。
報告書に掲載されている主要企業
・ AbbVie Inc.
・ Amgen Inc.
・ AstraZeneca plc
・ Biogen Inc.
・ Bristol-Myers Squibb Company
・ Celltrion, Inc.
・ Eli Lilly and Company
・ F. Hoffmann-La Roche Ltd.
・ Gilead Sciences, Inc.
・ Johnson ＆ Johnson
・ Merck ＆ Co.
・ Novo Nordisk A/S
・ Pfizer Inc.
・ Regeneron Pharmaceuticals, Inc.
・ Sanofi
2024年から2034年までのバイオ医薬品市場全体の世界売上高（金額ベース）は、2024年に4,700億米ドルを突破する。2034年まで力強い収益成長を予測している。当社の調査では、最も大きな可能性を秘めた組織を特定しています。彼らの能力、進歩、商業的展望を発見し、一歩先を行くお手伝いをします。
バイオ医薬品市場、2024〜2034年レポートはどのように役立つのでしょうか？
要約すると、310ページを超える本レポートは以下の知識を提供します：
- バイオ医薬品市場の2024年から2034年までの収益予測 製品、用途、製造タイプ、エンドユーザーごとの予測を世界および地域レベルで掲載 - 業界の将来性を発見し、投資と収益に最も有利な場所を見つけることができます。
- 5つの地域と22の主要国市場の2034年までの収益予測 - 北米、欧州、アジア太平洋、中南米、MEAのバイオ医薬品市場2024年から2034年までの市場予測をご覧ください。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなどの主要国の市場も予測しています。
- 2024年から2034年までのバイオ医薬品市場に関わる主要企業15社の企業プロファイルを含む。
独自の予測による定量的・定性的分析をご覧ください。私たちのレポートだけに含まれる情報を入手し、貴重なビジネスインテリジェンスで情報を得ることができます。
他にはない情報
私たちの新しいレポートがあれば、知識に遅れをとったり、チャンスを逃したりする可能性が低くなります。弊社のレポートが貴社の調査、分析、意思決定にどのように役立つかをご覧ください。Visiongainの調査は、生物製剤市場、2024年から2034年、市場をリードする企業の商業分析を必要とするすべての人のためのものです。データ、トレンド、予測をご覧いただけます。
ページTOPに戻る
目次
目次
1 レポートの概要
1.1 研究の目的
1.2 バイオ医薬品市場の紹介
1.3 本レポートの内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問
1.6 本レポートは誰のためのものか？
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問（FAQ）
1.9 Visiongainの関連レポート
1.10 Visiongainについて
2 エグゼクティブ・サマリー
3 市場概要
3.1 主要な調査結果
3.2 市場ダイナミクス
3.2.1 市場促進要因
3.2.1.1 生物製剤に対する需要の高まり
3.2.1.2 生物医学研究への高い資金援助
3.2.1.3 高齢者人口の増加が市場成長を促進する
3.2.1.4 慢性疾患の有病率の増加
3.2.2 市場抑制要因
3.2.2.1 生物製剤の特許切れ
3.2.2.2 生物製剤の高コスト
3.2.2.3 臨床試験の厳しさと回転率の低さ
3.2.3 市場機会
3.2.3.1 新興国におけるR&Dの拡大と優先化
3.2.3.2 ゲノミクスとプロテオミクスの重要性の高まり
3.2.3.3 生物製剤企業間の提携、M&A、パートナーシップ
3.3 COVID-19の影響分析
3.4 ポーターのファイブフォース分析
3.4.1 サプライヤーの交渉力
3.4.2 バイヤーの交渉力
3.4.3 競争相手のライバル関係
3.4.4 代替品による脅威
3.4.5 新規参入企業の脅威
3.5 PEST分析
4 バイオ医薬品市場分析：製品別
4.1 主要な調査結果
4.2 製品セグメント 市場魅力度指数
4.3 製品別バイオ医薬品市場規模の推定と予測
4.4 モノクローナル抗体
4.4.1 2024〜2034年の地域別市場規模（US$ Billion）
4.4.2 地域別市場シェア、2024年・2034年(%)
4.4.3 ヒト
4.4.3.1 2024〜2034年の地域別市場規模（US$ Billion）
4.4.3.2 地域別市場シェア、2024年・2034年(%)
4.4.4 ヒト化
4.4.4.1 2024〜2034年の地域別市場規模（US$ Billion）
4.4.4.2 地域別市場シェア、2024年・2034年(%)
4.4.5 キメラ
4.4.5.1 2024〜2034年の地域別市場規模（US$ Billion）
4.4.5.2 地域別市場シェア、2024年・2034年(%)
4.4.6 マウス
4.4.6.1 2024〜2034年の地域別市場規模（US$ Billion）
4.4.6.2 地域別市場シェア、2024年・2034年(%)
4.5 ワクチン
4.5.1 2024〜2034年の地域別市場規模（US$ Billion）
4.5.2 地域別市場シェア、2024年・2034年(%)
4.6 組換えタンパク質
4.6.1 2024〜2034年の地域別市場規模（US$ Billion）
4.6.2 地域別市場シェア、2024年・2034年(%)
4.7 再生医療
4.7.1 2024〜2034年の地域別市場規模（US$ Billion）
4.7.2 地域別市場シェア、2024年・2034年(%)
4.7.3 組織工学製品
4.7.3.1 2024〜2034年の地域別市場規模（US$ Billion）
4.7.3.2 地域別市場シェア、2024年・2034年(%)
4.7.4 細胞療法
4.7.4.1 2024〜2034年の地域別市場規模（US$ Billion）
4.7.4.2 地域別市場シェア、2024年・2034年(%)
4.7.5 遺伝子治療薬
4.7.5.1 2024〜2034年の地域別市場規模（US$ Billion）
4.7.5.2 地域別市場シェア、2024年・2034年(%)
4.8 その他
4.8.1 2024〜2034年の地域別市場規模（US$ Billion）
4.8.2 地域別市場シェア、2024年・2034年(%)
5 バイオ医薬品市場分析：用途別
5.1 主要な調査結果
5.2 アプリケーションセグメント 市場魅力度指数
5.3 バイオ医薬品の用途別市場規模の推定と予測
5.4 がん領域
5.4.1 2024〜2034年の地域別市場規模（US$ Billion）
5.4.2 地域別市場シェア、2024年・2034年(%)
5.5 感染症
5.5.1 2024〜2034年の地域別市場規模（US$ Billion）
5.5.2 2024年および2034年の地域別市場シェア(%)
5.6 自己免疫疾患
5.6.1 2024〜2034年の地域別市場規模（US$ Billion）
5.6.2 2024年および2034年の地域別市場シェア(%)
5.7 血液疾患
5.7.1 2024〜2034年の地域別市場規模（US$ Billion）
5.7.2 2024年および2034年の地域別市場シェア（%)
5.8 循環器疾患
5.8.1 2024〜2034年の地域別市場規模（US$ Billion）
5.8.2 2024年および2034年の地域別市場シェア（%)
5.9 その他
5.9.1 2024〜2034年の地域別市場規模（US$ Billion）
5.9.2 地域別市場シェア、2024年・2034年(%)
6 バイオ医薬品市場分析：製造タイプ別
6.1 主要な調査結果
6.2 製造タイプ別セグメント 市場魅力度指数
6.3 製造タイプ別バイオ医薬品市場規模の推定と予測
6.4 アウトソース
6.4.1 2024〜2034年の地域別市場規模（US$ Billion）
6.4.2 地域別市場シェア、2024年・2034年(%)
6.5 インハウス
6.5.1 2024年～2034年の地域別市場規模（US$ Billion）
6.5.2 地域別市場シェア、2024年・2034年(%)
7 バイオ医薬品市場分析：エンドユーザー別
7.1 主要調査結果
7.2 エンドユーザー区分 市場魅力度指数
7.3 エンドユーザー別バイオ医薬品市場規模の推定と予測
7.4 病院
7.4.1 2024〜2034年の地域別市場規模（US$ Billion）
7.4.2 地域別市場シェア、2024年・2034年(%)
7.5 専門センター
7.5.1 2024〜2034年の地域別市場規模（US$ Billion）
7.5.2 地域別市場シェア、2024年・2034年(%)
7.6 その他
7.6.1 2024〜2034年の地域別市場規模（US$ Billion）
7.6.2 地域別市場シェア、2024年・2034年(%)
8 バイオ医薬品市場分析：地域別
8.1 主要な調査結果
8.2 地域別市場規模の推定と予測
9 北米のバイオ医薬品市場分析
9.1 主要な調査結果
9.2 北米のバイオ医薬品市場魅力度指数
9.3 北米のバイオ医薬品国別市場、2024年、2029年、2034年（US$ Billion）
9.4 北米のバイオ医薬品市場規模推定と予測：国別
9.5 北米のバイオ医薬品市場規模推定と予測：製品別
9.6 北米のバイオ医薬品市場規模推定と予測：用途別
9.7 北米のバイオ医薬品市場規模推定と予測：製造タイプ別
9.8 北米のバイオ医薬品市場規模推定と予測：エンドユーザー別
9.9 米国のバイオ医薬品市場分析
9.10 カナダのバイオ医薬品市場分析
10 欧州のバイオ医薬品市場分析
10.1 主要な調査結果
10.2 欧州のバイオ医薬品市場魅力度指数
10.3 欧州のバイオ医薬品国別市場、2024年、2029年、2034年（US$ Billion）
10.4 欧州のバイオ医薬品市場規模推定と予測：国別
10.5 欧州のバイオ医薬品市場規模推定と予測：製品別
10.6 欧州のバイオ医薬品市場規模推定と予測：用途別
10.7 欧州のバイオ医薬品市場規模推定と予測：製造タイプ別
10.8 欧州のバイオ医薬品市場規模推定と予測：エンドユーザー別
10.9 ドイツのバイオ医薬品市場分析
10.10 イギリスのバイオ医薬品市場分析
10.11 フランスのバイオ医薬品市場分析
10.12 イタリアのバイオ医薬品市場分析
10.13 スペインのバイオ医薬品市場分析
10.14 ロシアのバイオ医薬品市場分析
10.15 その他の欧州のバイオ医薬品市場分析
11 アジアのバイオ医薬品市場分析
11.1 主要な調査結果
11.2 アジアのバイオ医薬品市場魅力度指数
11.3 アジアのバイオ医薬品国別市場2024年、2029年、2034年（US$ Billion）
11.4 アジアのバイオ医薬品市場規模推定と予測：国別
11.5 アジアのバイオ医薬品市場規模推定と予測：製品別
11.6 アジアのバイオ医薬品市場規模推定と予測：用途別
11.7 アジアのバイオ医薬品市場規模推定と予測：製造タイプ別
11.8 アジアのバイオ医薬品市場規模推定と予測：エンドユーザー別
11.9 日本のバイオ医薬品市場分析
11.10 中国のバイオ医薬品市場分析
11.11 インドのバイオ医薬品市場分析
11.12 オーストラリアのバイオ医薬品市場分析
11.13 韓国のバイオ医薬品市場分析
11.14 その他のアジアのバイオ医薬品市場分析
12 ラテンアメリカのバイオ医薬品市場分析
12.1 主要な調査結果
12.2 ラテンアメリカのバイオ医薬品市場魅力度指数
12.3 ラテンアメリカのバイオ医薬品国別市場、2024年、2029年、2034年（US$ Billion）
12.4 ラテンアメリカのバイオ医薬品市場規模推定と予測：国別
12.5 ラテンアメリカのバイオ医薬品市場規模推定と予測：製品別
12.6 ラテンアメリカのバイオ医薬品市場規模推定と予測：用途別
12.7 ラテンアメリカのバイオ医薬品市場規模推定と予測：製造タイプ別
12.8 ラテンアメリカのバイオ医薬品市場規模推定と予測：エンドユーザー別
12.9 ブラジルのバイオ医薬品市場分析
12.10 メキシコのバイオ医薬品市場分析
12.11 アルゼンチンのバイオ医薬品市場分析
12.12 その他のラテンアメリカのバイオ医薬品市場分析
13 MEAのバイオ医薬品市場分析
13.1 主要な調査結果
13.2 MEAのバイオ医薬品市場魅力度指数
13.3 MEAのバイオ医薬品国別市場、2024年、2029年、2034年（US$ Billion）
13.4 MEAのバイオ医薬品市場規模推定と予測：国別
13.5 MEAのバイオ医薬品市場規模推定と予測：製品別
13.6 MEAのバイオ医薬品市場規模推定と予測：用途別
13.7 MEAのバイオ医薬品市場規模推定と予測：製造タイプ別
13.8 MEAのバイオ医薬品市場規模推定と予測：エンドユーザー別
13.9 GCCのバイオ医薬品市場分析
13.10 南アフリカのバイオ医薬品市場分析
13.11 その他のMEAバイオ医薬品市場分析
14 主要企業のプロファイル
14.1 企業シェア分析、2022年
14.2 戦略的展望
14.3 Johnson & Johnson
14.3.1 会社概要
14.3.2 会社概要
14.3.3 財務分析
14.3.3.1 純収入,2017-2022
14.3.3.2 売上高,2017-2022
14.3.3.3 地域市場シェア、2022年
14.3.3.4 事業市場シェア、2022年
14.3.4 製品ベンチマーク
14.3.5 戦略的展望
14.4 F. Hoffmann-La Roche AG
14.4.1 会社概要
14.4.2 会社概要
14.4.3 財務分析
14.4.3.1 純収入、2017-2022年
14.4.3.2 R＆D、2017-2022年
14.4.3.3 地域市場シェア、2022年
14.4.3.4 事業市場シェア、2022年
14.4.4 製品ベンチマーク
14.4.5 戦略的展望
14.5 Amgen Inc.
14.5.1 会社概要
14.5.2 会社概要
14.5.3 財務分析
14.5.3.1 純収入、2017-2022年
14.5.3.2 R＆D、2017-2022年
14.5.3.3 地域市場シェア、2022年
14.5.3.4 事業市場シェア、2022年
14.5.4 製品ベンチマーク
14.5.5 戦略的展望
14.6 AbbVie Inc.
14.6.1 会社概要
14.6.2 会社概要
14.6.3 財務分析
14.6.3.1 純収入、2017-2022年
14.6.3.2 R＆D、2017年〜2022年
14.6.3.3 地域市場シェア、2022年
14.6.4 製品ベンチマーク
14.6.5 戦略的展望
14.7 Novo Nordisk A/S
14.7.1 会社概要
14.7.2 会社概要
14.7.3 財務分析
14.7.3.1 純収入、2017-2022年
14.7.3.2 R＆D、2017-2022年
14.7.3.3 地域市場シェア、2022年
14.7.3.4 事業市場シェア、2022年
14.7.4 製品ベンチマーク
14.7.5 戦略的展望
14.8 Eli Lilly and Company
14.8.1 会社概要
14.8.2 会社概要
14.8.3 財務分析
14.8.3.1 純収入、2017-2022年
14.8.3.2 R＆D、2017-2022年
14.8.3.3 地域市場シェア、2022年
14.8.3.4 事業市場シェア、2022年
14.8.4 製品ベンチマーク
14.8.5 戦略的展望
14.9 Bristol-Myers Squibb Company
14.9.1 会社概要
14.9.2 会社概要
14.9.3 財務分析
14.9.3.1 純収入、2017-2022年
14.9.3.2 R＆D、2017-2022年
14.9.3.3 地域市場シェア、2022年
14.9.3.4 事業市場シェア、2022年
14.9.4 製品ベンチマーク
14.9.5 戦略的展望
14.10 Merck & Co.
14.10.1 会社概要
14.10.2 会社概要
14.10.3 財務分析
14.10.3.1 純収入、2017-2022年
14.10.3.2 売上高、2017-2022年
14.10.3.3 地域市場シェア、2022年
14.10.3.4 事業市場シェア、2022年
14.10.4 製品ベンチマーク
14.10.5 戦略的展望
14.11 AstraZeneca plc
14.11.1 会社概要
14.11.2 会社概要
14.11.3 財務分析
14.11.3.1 純収入、2017-2022年
14.11.3.2 R＆D、2017年〜2022年
14.11.3.3 地域市場シェア、2022年
14.11.3.4 事業市場シェア、2022年
14.11.4 製品ベンチマーク
14.11.5 戦略的展望
14.12 Sanofi
14.12.1 会社概要
14.12.2 会社概要
14.12.3 財務分析
14.12.3.1 純収入、2017-2022年
14.12.3.2 R＆D、2017-2022年
14.12.3.3 地域市場シェア、2022年
14.12.3.4 事業市場シェア、2022年
14.12.4 製品ベンチマーク
14.12.5 戦略的展望
14.13 Pfizer Inc.
14.13.1 会社概要
14.13.2 会社概要
14.13.3 財務分析
14.13.3.1 純収入、2017-2022年
14.13.3.2 R＆D、2017年～2022年
14.13.3.3 地域市場シェア、2023年
14.13.3.4 事業市場シェア、2023年
14.13.4 製品ベンチマーク
14.13.5 戦略的展望
14.14 Regeneron Pharmaceuticals, Inc.
14.14.1 会社概要
14.14.2 会社概要
14.14.3 財務分析
14.14.3.1 純収入,2017-2022
14.14.3.2 R＆D,2017-2022年
14.14.3.3 事業市場シェア、2022年
14.14.4 製品ベンチマーク
14.14.5 戦略的展望
14.15 Gilead Sciences, Inc.
14.15.1 会社概要
14.15.2 会社概要
14.15.3 財務分析
14.15.3.1 純収入,2017-2022
14.15.3.2 売上高,2017-2022
14.15.3.3 地域市場シェア、2022年
14.15.3.4 事業市場シェア、2022年
14.15.4 製品ベンチマーク
14.15.5 戦略的展望
14.16 Celltrion, Inc.
14.16.1 会社概要
14.16.2 会社概要
14.16.3 財務分析
14.16.3.1 純収入、2017-2022年
14.16.4 製品ベンチマーク
14.16.5 戦略的展望
14.17 Biogen Inc.
14.17.1 会社概要
14.17.2 会社概要
14.17.3 財務分析
14.17.3.1 純収入、2017-2022年
14.17.3.2 R＆D、2017-2022年
14.17.3.3 地域市場シェア、2022年
14.17.4 製品ベンチマーク
14.17.5 戦略的展望
15 結論と提言
15.1 Visiongainからの結びの言葉
15.2 市場プレイヤーへの提言
ページTOPに戻る
図表リスト
表の一覧
Table 1 Biologics Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
Table 2 Collaboration, M&A, and Partnerships among Biologics Companies
Table 3 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 4 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “U” Shaped Recovery
Table 5 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “W” Shaped Recovery
Table 6 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 7 Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 8 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 9 Human Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 10 Humanized Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 11 Chimeric Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 12 Murine Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 13 Vaccines Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 14 Recombinant Proteins Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 15 Regenerative Medicine Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 16 Tissue Engineered Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 17 Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 18 Gene Therapies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 19 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 20 Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 21 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 22 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 23 Autoimmune Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 24 Haematological Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 25 Cardiovascular Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 26 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 28 Outsource Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 29 In-house Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 31 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 32 Speciality Centres Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 33 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 34 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 35 North America Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 36 North America Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 37 North America Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 38 North America Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 39 North America Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 40 U.S. Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 41 Canada Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 42 Europe Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 43 Europe Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 44 Europe Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 45 Europe Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 46 Europe Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 47 Germany Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 48 UK Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 49 France Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 50 Italy Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 51 Spain Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 52 Russia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 53 Rest of Europe Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 54 Asia Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 55 Asia Pacific Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 56 Asia Pacific Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 57 Asia Pacific Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 58 Asia Pacific Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 59 Japan Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 60 China Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 61 India Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 62 Australia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 63 South Korea Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 64 Rest of Asia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 65 Latin America Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 66 Latin America Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 67 Latin America Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 68 Latin America Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 69 Latin America Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 70 Brazil Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 71 Mexico Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 72 Argentina Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 73 Rest of Latin America Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 74 MEA Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 75 MEA Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 76 MEA Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 77 MEA Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 78 MEA Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 79 GCC Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 80 South Africa Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 81 Rest of MEA Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 82 Strategic Outlook
Table 83 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Johnson & Johnson: Product Benchmarking
Table 85 Johnson & Johnson: Strategic Outlook
Table 86 F. Hoffmann-La Roche AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 F. Hoffmann-La Roche AG: Product Benchmarking
Table 88 F. Hoffmann-La Roche AG: Strategic Outlook
Table 89 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Amgen Inc.: Product Benchmarking
Table 91 Amgen Inc. Strategic Outlook
Table 92 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 AbbVie Inc.: Product Benchmarking
Table 94 AbbVie Inc.: Strategic Outlook
Table 95 Novo Nordisk A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Novo Nordisk A/S: Product Benchmarking
Table 97 Novo Nordisk A/S Strategic Outlook
Table 98 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Eli Lilly and Company: Product Benchmarking
Table 100 Eli Lilly and Company Strategic Outlook
Table 101 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Bristol-Myers Squibb Company: Product Benchmarking
Table 103 Bristol-Myers Squibb Company Strategic Outlook
Table 104 Merck & Co.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Merck & Co.: Product Benchmarking
Table 106 Merck & Co.: Strategic Outlook
Table 107 AstraZeneca plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 AstraZeneca plc: Product Benchmarking
Table 109 AstraZeneca plc Strategic Outlook
Table 110 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 Sanofi: Product Benchmarking
Table 112 Sanofi Strategic Outlook
Table 113 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 114 Pfizer Inc.: Product Benchmarking
Table 115 Pfizer Inc.: Strategic Outlook
Table 116 Regeneron Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 117 Regeneron Pharmaceuticals, Inc.: Product Benchmarking
Table 118 Regeneron Pharmaceuticals, Inc.: Strategic Outlook
Table 119 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 Gilead Sciences, Inc.: Product Benchmarking
Table 121 Gilead Sciences, Inc.: Strategic Outlook
Table 122 Celltrion, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Celltrion, Inc.: Product Benchmarking
Table 124 Celltrion, Inc. Strategic Outlook
Table 125 Biogen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Biogen Inc.: Product Benchmarking
Table 127 Biogen Inc. Strategic Outlook
図の一覧
Figure 1 Biologics Market Segmentation
Figure 2 Biologics Market by Product: Market Attractiveness Index
Figure 3 Biologics Market by Application: Market Attractiveness Index
Figure 4 Biologics Market by Manufacturing Type: Market Attractiveness Index
Figure 5 Biologics Market by End-users: Market Attractiveness Index
Figure 6 Biologics Market Attractiveness Index by Region
Figure 7 Biologics Market: Market Dynamics
Figure 8 NIH Program Level Budget 2016-2023 (US$ Bn)
Figure 9 Global Population Aged 65+, 2022 (Million)
Figure 10 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %): “V” Shaped Recovery
Figure 11 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %): “U” Shaped Recovery
Figure 12 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %): “W” Shaped Recovery
Figure 13 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %): “L” Shaped Recovery
Figure 14 Biologics Market: Porter’s Five Forces Analysis
Figure 15 Biologics Market: PEST Analysis
Figure 16 Biologics Market by Product: Market Attractiveness Index
Figure 17 Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 18 Biologics Share Forecast by Product, 2024, 2029, 2034 (%)
Figure 19 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 20 Monoclonal Antibodies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 Human Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 22 Human Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 23 Humanized Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 24 Humanized Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 25 Chimeric Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 26 Chimeric Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 27 Murine Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 28 Murine Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Vaccines Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 30 Vaccines Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Recombinant Proteins Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 32 Recombinant Proteins Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 33 Regenerative Medicine Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 34 Regenerative Medicine Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 35 Tissue Engineered Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 36 Tissue Engineered Products Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 37 Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 38 Cell Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Gene Therapies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 40 Gene Therapies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 42 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Biologics Market by Application: Market Attractiveness Index
Figure 44 Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 45 Biologics Share Forecast by Application, 2024, 2029, 2034 (%)
Figure 46 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 47 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 48 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 49 Infectious Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Autoimmune Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 51 Autoimmune Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 52 Haematological Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 53 Haematological Disorders Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 54 Cardiovascular Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 55 Cardiovascular Disorders Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 56 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 57 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 58 Biologics Market by Manufacturing Type: Market Attractiveness Index
Figure 59 Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
Figure 60 Biologics Share Forecast by Manufacturing Type, 2024, 2029, 2034 (%)
Figure 61 Outsource Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 62 Outsource Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 63 In-house Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 64 In-house Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 65 Biologics Market by End-users: Market Attractiveness Index
Figure 66 Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 67 Biologics Share Forecast by End-users, 2024, 2029, 2034 (%)
Figure 68 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 69 Hospitals Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 70 Speciality Centres Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 71 Speciality Centres Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 72 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 73 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 74 Biologics Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 75 Biologics Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 76 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %)
Figure 77 North America Biologics Market Attractiveness Index
Figure 78 North America Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 79 North America Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 80 North America Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 81 North America Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 82 North America Biologics Market Share Forecast by Product, 2024 & 2034 (%)
Figure 83 North America Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 84 North America Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 85 North America Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
Figure 86 North America Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
Figure 87 North America Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 88 North America Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 89 U.S. Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 90 Canada Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 91 Europe Biologics Market Attractiveness Index
Figure 92 Europe Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 93 Europe Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 94 Europe Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 95 Europe Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 96 Europe Biologics Market Share Forecast by Product, 2024 & 2034 (%)
Figure 97 Europe Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 98 Europe Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 99 Europe Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
Figure 100 Europe Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
Figure 101 Europe Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 102 Europe Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 103 Germany Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 104 UK Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 105 France Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 106 Italy Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 107 Spain Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 108 Russia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 109 Rest of Europe Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 110 Asia Biologics Market Attractiveness Index
Figure 111 Asia Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 112 Asia Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 113 Asia Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 114 Asia Pacific Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 115 Asia Pacific Biologics Market Share Forecast by Product, 2024 & 2034 (%)
Figure 116 Asia Pacific Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 117 Asia Pacific Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 118 Asia Pacific Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
Figure 119 Asia Pacific Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
Figure 120 Asia Pacific Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 121 Asia Pacific Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 122 Japan Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 123 China Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 124 India Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 125 Australia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 126 South Korea Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 127 Rest of Asia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 128 Latin America Biologics Market Attractiveness Index
Figure 129 Latin America Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 130 Latin America Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 131 Latin America Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 132 Latin America Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 133 Latin America Biologics Market Share Forecast by Product, 2024 & 2034 (%)
Figure 134 Latin America Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 135 Latin America Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 136 Latin America Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
Figure 137 Latin America Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
Figure 138 Latin America Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 139 Latin America Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 140 Brazil Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 141 Mexico Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 142 Argentina Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 143 Rest of Latin America Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 144 MEA Biologics Market Attractiveness Index
Figure 145 MEA Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 146 MEA Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 147 MEA Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 148 MEA Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 149 MEA Biologics Market Share Forecast by Product, 2024 & 2034 (%)
Figure 150 MEA Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 151 MEA Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 152 MEA Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
Figure 153 MEA Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
Figure 154 MEA Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 155 MEA Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 156 GCC Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 157 South Africa Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 158 Rest of MEA Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 159 Biologics Market: Company Share Analysis, 2022
Figure 160 Johnson & Johnson: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 161 Johnson & Johnson: R&D, 2017-2022 (US$ Million, AGR%)
Figure 162 Johnson & Johnson: Regional Market Shares, 2022
Figure 163 Johnson & Johnson: Business Market Shares, 2022
Figure 164 F. Hoffmann-La Roche AG: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 165 F. Hoffmann-La Roche AG: R&D, 2017-2022 (US$ Million, AGR%)
Figure 166 F. Hoffmann-La Roche AG: Regional Market Shares, 2022
Figure 167 F. Hoffmann-La Roche AG: Business Market Shares, 2022
Figure 168 Amgen Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 169 Amgen Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 170 Amgen Inc.: Regional Market Shares, 2022
Figure 171 Amgen Inc.: Business Market Shares, 2022
Figure 172 AbbVie Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 173 AbbVie Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 174 AbbVie Inc.: Regional Market Shares, 2022
Figure 175 Novo Nordisk A/S: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 176 Novo Nordisk A/S: R&D, 2017-2022 (US$ Million, AGR%)
Figure 177 Novo Nordisk A/S: Regional Market Shares, 2022
Figure 178 Novo Nordisk A/S: Business Market Shares, 2022
Figure 179 Eli Lilly and Company: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 180 Eli Lilly and Company: R&D, 2017-2022 (US$ Million, AGR%)
Figure 181 Eli Lilly and Company: Regional Market Shares, 2022
Figure 182 Eli Lilly and Company: Business Market Shares, 2022
Figure 183 Bristol-Myers Squibb Company: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 184 Bristol-Myers Squibb Company: R&D, 2017-2022 (US$ Million, AGR%)
Figure 185 Bristol-Myers Squibb Company: Regional Market Shares, 2022
Figure 186 Bristol-Myers Squibb Company: Business Market Shares, 2022
Figure 187 Merck & Co.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 188 Merck & Co.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 189 Merck & Co.: Regional Market Shares, 2022
Figure 190 Merck & Co.: Business Market Shares, 2022
Figure 191 AstraZeneca plc: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 192 AstraZeneca plc: R&D, 2017-2022 (US$ Million, AGR%)
Figure 193 AstraZeneca plc: Regional Market Shares, 2022
Figure 194 AstraZeneca plc: Business Market Shares, 2022
Figure 195 Sanofi: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 196 Sanofi: R&D, 2017-2022 (US$ Million, AGR%)
Figure 197 Sanofi: Regional Market Shares, 2022
Figure 198 Sanofi: Business Market Shares, 2022
Figure 199 Pfizer Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 200 Pfizer Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 201 Pfizer Inc.: Regional Market Shares, 2023
Figure 202 Pfizer Inc.: Business Market Shares, 2022
Figure 203 Regeneron Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 204 Regeneron Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 205 Regeneron Pharmaceuticals, Inc.: Business Market Shares, 2022
Figure 206 Gilead Sciences, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 207 Gilead Sciences, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 208 Gilead Sciences, Inc.: Regional Market Shares, 2022
Figure 209 Gilead Sciences, Inc: Business Market Shares, 2022
Figure 210 Celltrion, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 211 Biogen Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 212 Biogen Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 213 Biogen Inc.: Regional Market Shares, 2022
ページTOPに戻る
Summary
Report Details
The Biologics Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Advances in Regenerative Medicine and Cell Biology Driving Market Growth
Advancements in cell biology and regenerative medicine are driving market growth by laying a robust foundation for stem cell-based therapies targeting a range of disorders, including cardiovascular, oncological, metabolic, and musculoskeletal conditions. These groundbreaking treatments offer global patients the potential for transformative strategies in handling complex medical challenges. Continued exploration and innovation in this field are poised to achieve further milestones, ushering in a future where debilitating illnesses can be effectively managed, and in some cases, even eliminated. Companies like Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics leverage CRISPR-Cas9 gene editing technology for potential gene therapies and regenerative medicine applications, aiming to rectify genetic disorders at the molecular level. Additionally, Vericel’s FDA-approved MACI (Matrix-Induced Autologous Chondrocyte Implantation) utilizes a patient’s own cells to repair knee cartilage defects.
Challenges Posed by Patent Expiration for Biologics
The expiration of patents on the initial biologics generation is paving the way for increased competition as biosimilars are poised to enter the market soon. Biosimilars, designed to replicate the qualities of previously approved biologic therapies, are gaining momentum worldwide, driven by governments aiming to reduce healthcare costs. Notably, the Central Drugs Standard Control Organization (CDSCO) in India has introduced the “Guidelines on Similar Biologics” to boost the Indian biosimilars industry. The biologics field in biotechnology is rapidly evolving, with over 60% dedicated to treating diabetes, autoimmune disorders, and cancer, resulting in high and escalating costs. Recognizing the barrier posed by these high prices, the World Health Organization (WHO) highlights an opportunity for generic drug manufacturers to produce biosimilar versions as patents expire. Generic drug producers are actively seeking biologics with impending patent expirations, with 230 drug patents set to expire between 2021 and 2025. Notable biologics expiring in 2024 include PERJETA (Pertuzumab), VYROLOGIX (Leronlimab), and STELARA (Ustekinumab). The Center for Biosimilars notes that while biologics currently constitute half of the oncology pharmaceutical industry, the expiration of nearly 20 oncology biologics’ patents by 2024 could lead to increased use of biosimilars in cancer treatment, contributing to lower overall costs.
What Questions Should You Ask before Buying a Market Research Report?
• How is the biologics market evolving?
• What is driving and restraining the biologics market?
• How will each biologics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each biologics submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading biologics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the biologics projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of biologics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the biologics market?
• Where is the biologics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the biologics market today, and over the next 10 years:
• Our 312-page report provides 127 tables and 213 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the biologics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising biologics prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Product Outlook
• Monoclonal Antibodies
– Human
– Humanized
– Chimeric
– Murine
• Vaccines
• Recombinant Proteins
• Regenerative Medicine
– Tissue Engineered Products
– Cell Therapy
– Gene Therapies
• Others
Application
• Oncology
• Infectious Diseases
• Autoimmune Disease
• Haematological Disorder
• Cardiovascular Disorders
• Others
Manufacturing Type
• Outsource
• In-house
End-users
• Hospitals
• Speciality Centres
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
The report also includes profiles and for some of the leading companies in the Biologics Market, 2024 to 2034, with a focus on this segment of these companies’ operations.
Leading companies profiled in the report
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Biogen Inc.
• Bristol-Myers Squibb Company
• Celltrion, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• Johnson & Johnson
• Merck & Co.
• Novo Nordisk A/S
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi
Overall world revenue for Biologics Market, 2024 to 2034 in terms of value the market will surpass US$470.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Biologics Market, 2024 to 2034 report help you?
In summary, our 310+ page report provides you with the following knowledge:
• Revenue forecasts to 2034 for Biologics Market, 2024 to 2034 Market, with forecasts for product, application, manufacturing type, and end-users, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 22 key national markets – See forecasts for the Biologics Market, 2024 to 2034 market in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 15 of the major companies involved in the Biologics Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Biologics Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
ページTOPに戻る
Table of Contents
Table of Contents
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Biologics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Rising Demand for Biologics
3.2.1.2 High Funding for Biomedical Research
3.2.1.3 Increase in Number of Elderly Population will Drive the Market Growth
3.2.1.4 Increasing Prevalence of Chronic Diseases
3.2.2 Market Restraining Factors
3.2.2.1 Patent Expiration for Biologics
3.2.2.2 High Cost of Biologics
3.2.2.3 High Stringency and Low Turnover for Clinical Trials
3.2.3 Market Opportunities
3.2.3.1 Emerging Economies Expansion and Prioritisation of R&D
3.2.3.2 Growing Significance of Genomics and Proteomics
3.2.3.3 Collaboration, M&A, and Partnerships among Biologics Companies
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
4 Biologics Market Analysis by Product
4.1 Key Findings
4.2 Product Segment: Market Attractiveness Index
4.3 Biologics Market Size Estimation and Forecast by Product
4.4 Monoclonal Antibodies
4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.4.3 Human
4.4.3.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.3.2 Market Share by Region, 2024 & 2034 (%)
4.4.4 Humanized
4.4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.4.2 Market Share by Region, 2024 & 2034 (%)
4.4.5 Chimeric
4.4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.5.2 Market Share by Region, 2024 & 2034 (%)
4.4.6 Murine
4.4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.6.2 Market Share by Region, 2024 & 2034 (%)
4.5 Vaccines
4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Recombinant Proteins
4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
4.6.2 Market Share by Region, 2024 & 2034 (%)
4.7 Regenerative Medicine
4.7.1 Market Size by Region, 2024-2034 (US$ Billion)
4.7.2 Market Share by Region, 2024 & 2034 (%)
4.7.3 Tissue Engineered Products
4.7.3.1 Market Size by Region, 2024-2034 (US$ Billion)
4.7.3.2 Market Share by Region, 2024 & 2034 (%)
4.7.4 Cell Therapy
4.7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.7.4.2 Market Share by Region, 2024 & 2034 (%)
4.7.5 Gene Therapies
4.7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.7.5.2 Market Share by Region, 2024 & 2034 (%)
4.8 Others
4.8.1 Market Size by Region, 2024-2034 (US$ Billion)
4.8.2 Market Share by Region, 2024 & 2034 (%)
5 Biologics Market Analysis by Application
5.1 Key Findings
5.2 Application Segment: Market Attractiveness Index
5.3 Biologics Market Size Estimation and Forecast by Application
5.4 Oncology
5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Infectious Diseases
5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Autoimmune Diseases
5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
5.6.2 Market Share by Region, 2024 & 2034 (%)
5.7 Haematological Disorders
5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 Cardiovascular Disorders
5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
5.8.2 Market Share by Region, 2024 & 2034 (%)
5.9 Others
5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
5.9.2 Market Share by Region, 2024 & 2034 (%)
6 Biologics Market Analysis by Manufacturing Type
6.1 Key Findings
6.2 Manufacturing Type Segment: Market Attractiveness Index
6.3 Biologics Market Size Estimation and Forecast by Manufacturing Type
6.4 Outsource
6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 In-house
6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
6.5.2 Market Share by Region, 2024 & 2034 (%)
7 Biologics Market Analysis by End-users
7.1 Key Findings
7.2 End-users Segment: Market Attractiveness Index
7.3 Biologics Market Size Estimation and Forecast by End-users
7.4 Hospitals
7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Speciality Centres
7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Others
7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
7.6.2 Market Share by Region, 2024 & 2034 (%)
8 Biologics Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 North America Biologics Market Analysis
9.1 Key Findings
9.2 North America Biologics Market Attractiveness Index
9.3 North America Biologics Market by Country, 2024, 2029 & 2034 (US$ Billion)
9.4 North America Biologics Market Size Estimation and Forecast by Country
9.5 North America Biologics Market Size Estimation and Forecast by Product
9.6 North America Biologics Market Size Estimation and Forecast by Application
9.7 North America Biologics Market Size Estimation and Forecast by Manufacturing Type
9.8 North America Biologics Market Size Estimation and Forecast by End-users
9.9 U.S. Biologics Market Analysis
9.10 Canada Biologics Market Analysis
10 Europe Biologics Market Analysis
10.1 Key Findings
10.2 Europe Biologics Market Attractiveness Index
10.3 Europe Biologics Market by Country, 2024, 2029 & 2034 (US$ Billion)
10.4 Europe Biologics Market Size Estimation and Forecast by Country
10.5 Europe Biologics Market Size Estimation and Forecast by Product
10.6 Europe Biologics Market Size Estimation and Forecast by Application
10.7 Europe Biologics Market Size Estimation and Forecast by Manufacturing Type
10.8 Europe Biologics Market Size Estimation and Forecast by End-users
10.9 Germany Biologics Market Analysis
10.10 UK Biologics Market Analysis
10.11 France Biologics Market Analysis
10.12 Italy Biologics Market Analysis
10.13 Spain Biologics Market Analysis
10.14 Russia Biologics Market Analysis
10.15 Rest of Europe Biologics Market Analysis
11 Asia Biologics Market Analysis
11.1 Key Findings
11.2 Asia Biologics Market Attractiveness Index
11.3 Asia Biologics Market by Country, 2024, 2029 & 2034 (US$ Billion)
11.4 Asia Biologics Market Size Estimation and Forecast by Country
11.5 Asia Pacific Biologics Market Size Estimation and Forecast by Product
11.6 Asia Pacific Biologics Market Size Estimation and Forecast by Application
11.7 Asia Pacific Biologics Market Size Estimation and Forecast by Manufacturing Type
11.8 Asia Pacific Biologics Market Size Estimation and Forecast by End-users
11.9 Japan Biologics Market Analysis
11.10 China Biologics Market Analysis
11.11 India Biologics Market Analysis
11.12 Australia Biologics Market Analysis
11.13 South Korea Biologics Market Analysis
11.14 Rest of Asia Biologics Market Analysis
12 Latin America Biologics Market Analysis
12.1 Key Findings
12.2 Latin America Biologics Market Attractiveness Index
12.3 Latin America Biologics Market by Country, 2024, 2029 & 2034 (US$ Billion)
12.4 Latin America Biologics Market Size Estimation and Forecast by Country
12.5 Latin America Biologics Market Size Estimation and Forecast by Product
12.6 Latin America Biologics Market Size Estimation and Forecast by Application
12.7 Latin America Biologics Market Size Estimation and Forecast by Manufacturing Type
12.8 Latin America Biologics Market Size Estimation and Forecast by End-users
12.9 Brazil Biologics Market Analysis
12.10 Mexico Biologics Market Analysis
12.11 Argentina Biologics Market Analysis
12.12 Rest of Latin America Biologics Market Analysis
13 MEA Biologics Market Analysis
13.1 Key Findings
13.2 MEA Biologics Market Attractiveness Index
13.3 MEA Biologics Market by Country, 2024, 2029 & 2034 (US$ Billion)
13.4 MEA Biologics Market Size Estimation and Forecast by Country
13.5 MEA Biologics Market Size Estimation and Forecast by Product
13.6 MEA Biologics Market Size Estimation and Forecast by Application
13.7 MEA Biologics Market Size Estimation and Forecast by Manufacturing Type
13.8 MEA Biologics Market Size Estimation and Forecast by End-users
13.9 GCC Biologics Market Analysis
13.10 South Africa Biologics Market Analysis
13.11 Rest of MEA Biologics Market Analysis
14 Company Profiles
14.1 Company Share Analysis, 2022
14.2 Strategic Outlook
14.3 Johnson & Johnson
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue,2017-2022
14.3.3.2 R&D,2017-2022
14.3.3.3 Regional Market Shares, 2022
14.3.3.4 Business Market Shares, 2022
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 F. Hoffmann-La Roche AG
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2017-2022
14.4.3.2 R&D, 2017-2022
14.4.3.3 Regional Market Shares, 2022
14.4.3.4 Business Market Shares, 2022
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 Amgen Inc.
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Net Revenue, 2017-2022
14.5.3.2 R&D, 2017-2022
14.5.3.3 Regional Market Shares, 2022
14.5.3.4 Business Market Shares, 2022
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 AbbVie Inc.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2017-2022
14.6.3.2 R&D, 2017-2022
14.6.3.3 Regional Market Shares, 2022
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Novo Nordisk A/S
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Net Revenue, 2017-2022
14.7.3.2 R&D, 2017-2022
14.7.3.3 Regional Market Shares, 2022
14.7.3.4 Business Market Shares, 2022
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.8 Eli Lilly and Company
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Net Revenue, 2017-2022
14.8.3.2 R&D, 2017-2022
14.8.3.3 Regional Market Shares, 2022
14.8.3.4 Business Market Shares, 2022
14.8.4 Product Benchmarking
14.8.5 Strategic Outlook
14.9 Bristol-Myers Squibb Company
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Net Revenue, 2017-2022
14.9.3.2 R&D, 2017-2022
14.9.3.3 Regional Market Shares, 2022
14.9.3.4 Business Market Shares, 2022
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 Merck & Co.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Net Revenue, 2017-2022
14.10.3.2 R&D, 2017-2022
14.10.3.3 Regional Market Shares, 2022
14.10.3.4 Business Market Shares, 2022
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook
14.11 AstraZeneca plc
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Net Revenue, 2017-2022
14.11.3.2 R&D, 2017-2022
14.11.3.3 Regional Market Shares, 2022
14.11.3.4 Business Market Shares, 2022
14.11.4 Product Benchmarking
14.11.5 Strategic Outlook
14.12 Sanofi
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Net Revenue, 2017-2022
14.12.3.2 R&D, 2017-2022
14.12.3.3 Regional Market Shares, 2022
14.12.3.4 Business Market Shares, 2022
14.12.4 Product Benchmarking
14.12.5 Strategic Outlook
14.13 Pfizer Inc.
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Net Revenue, 2017-2022
14.13.3.2 R&D, 2017-2022
14.13.3.3 Regional Market Shares, 2023
14.13.3.4 Business Market Shares, 2023
14.13.4 Product Benchmarking
14.13.5 Strategic Outlook
14.14 Regeneron Pharmaceuticals, Inc.
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Financial Analysis
14.14.3.1 Net Revenue,2017-2022
14.14.3.2 R&D,2017-2022
14.14.3.3 Business Market Shares, 2022
14.14.4 Product Benchmarking
14.14.5 Strategic Outlook
14.15 Gilead Sciences, Inc.
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Net Revenue,2017-2022
14.15.3.2 R&D,2017-2022
14.15.3.3 Regional Market Shares, 2022
14.15.3.4 Business Market Shares, 2022
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 Celltrion, Inc.
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Financial Analysis
14.16.3.1 Net Revenue, 2017-2022
14.16.4 Product Benchmarking
14.16.5 Strategic Outlook
14.17 Biogen Inc.
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Financial Analysis
14.17.3.1 Net Revenue, 2017-2022
14.17.3.2 R&D, 2017-2022
14.17.3.3 Regional Market Shares, 2022
14.17.4 Product Benchmarking
14.17.5 Strategic Outlook
15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players
ページTOPに戻る
List of Tables/Graphs
List of Tables
Table 1 Biologics Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
Table 2 Collaboration, M&A, and Partnerships among Biologics Companies
Table 3 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 4 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “U” Shaped Recovery
Table 5 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “W” Shaped Recovery
Table 6 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 7 Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 8 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 9 Human Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 10 Humanized Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 11 Chimeric Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 12 Murine Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 13 Vaccines Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 14 Recombinant Proteins Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 15 Regenerative Medicine Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 16 Tissue Engineered Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 17 Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 18 Gene Therapies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 19 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 20 Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 21 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 22 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 23 Autoimmune Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 24 Haematological Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 25 Cardiovascular Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 26 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 28 Outsource Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 29 In-house Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 31 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 32 Speciality Centres Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 33 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 34 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 35 North America Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 36 North America Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 37 North America Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 38 North America Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 39 North America Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 40 U.S. Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 41 Canada Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 42 Europe Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 43 Europe Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 44 Europe Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 45 Europe Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 46 Europe Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 47 Germany Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 48 UK Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 49 France Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 50 Italy Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 51 Spain Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 52 Russia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 53 Rest of Europe Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 54 Asia Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 55 Asia Pacific Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 56 Asia Pacific Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 57 Asia Pacific Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 58 Asia Pacific Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 59 Japan Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 60 China Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 61 India Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 62 Australia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 63 South Korea Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 64 Rest of Asia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 65 Latin America Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 66 Latin America Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 67 Latin America Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 68 Latin America Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 69 Latin America Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 70 Brazil Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 71 Mexico Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 72 Argentina Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 73 Rest of Latin America Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 74 MEA Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 75 MEA Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 76 MEA Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 77 MEA Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 78 MEA Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 79 GCC Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 80 South Africa Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 81 Rest of MEA Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 82 Strategic Outlook
Table 83 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Johnson & Johnson: Product Benchmarking
Table 85 Johnson & Johnson: Strategic Outlook
Table 86 F. Hoffmann-La Roche AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 F. Hoffmann-La Roche AG: Product Benchmarking
Table 88 F. Hoffmann-La Roche AG: Strategic Outlook
Table 89 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Amgen Inc.: Product Benchmarking
Table 91 Amgen Inc. Strategic Outlook
Table 92 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 AbbVie Inc.: Product Benchmarking
Table 94 AbbVie Inc.: Strategic Outlook
Table 95 Novo Nordisk A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Novo Nordisk A/S: Product Benchmarking
Table 97 Novo Nordisk A/S Strategic Outlook
Table 98 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Eli Lilly and Company: Product Benchmarking
Table 100 Eli Lilly and Company Strategic Outlook
Table 101 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Bristol-Myers Squibb Company: Product Benchmarking
Table 103 Bristol-Myers Squibb Company Strategic Outlook
Table 104 Merck & Co.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Merck & Co.: Product Benchmarking
Table 106 Merck & Co.: Strategic Outlook
Table 107 AstraZeneca plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 AstraZeneca plc: Product Benchmarking
Table 109 AstraZeneca plc Strategic Outlook
Table 110 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 Sanofi: Product Benchmarking
Table 112 Sanofi Strategic Outlook
Table 113 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 114 Pfizer Inc.: Product Benchmarking
Table 115 Pfizer Inc.: Strategic Outlook
Table 116 Regeneron Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 117 Regeneron Pharmaceuticals, Inc.: Product Benchmarking
Table 118 Regeneron Pharmaceuticals, Inc.: Strategic Outlook
Table 119 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 Gilead Sciences, Inc.: Product Benchmarking
Table 121 Gilead Sciences, Inc.: Strategic Outlook
Table 122 Celltrion, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Celltrion, Inc.: Product Benchmarking
Table 124 Celltrion, Inc. Strategic Outlook
Table 125 Biogen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Biogen Inc.: Product Benchmarking
Table 127 Biogen Inc. Strategic Outlook
List of Figures
Figure 1 Biologics Market Segmentation
Figure 2 Biologics Market by Product: Market Attractiveness Index
Figure 3 Biologics Market by Application: Market Attractiveness Index
Figure 4 Biologics Market by Manufacturing Type: Market Attractiveness Index
Figure 5 Biologics Market by End-users: Market Attractiveness Index
Figure 6 Biologics Market Attractiveness Index by Region
Figure 7 Biologics Market: Market Dynamics
Figure 8 NIH Program Level Budget 2016-2023 (US$ Bn)
Figure 9 Global Population Aged 65+, 2022 (Million)
Figure 10 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %): “V” Shaped Recovery
Figure 11 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %): “U” Shaped Recovery
Figure 12 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %): “W” Shaped Recovery
Figure 13 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %): “L” Shaped Recovery
Figure 14 Biologics Market: Porter’s Five Forces Analysis
Figure 15 Biologics Market: PEST Analysis
Figure 16 Biologics Market by Product: Market Attractiveness Index
Figure 17 Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 18 Biologics Share Forecast by Product, 2024, 2029, 2034 (%)
Figure 19 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 20 Monoclonal Antibodies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 Human Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 22 Human Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 23 Humanized Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 24 Humanized Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 25 Chimeric Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 26 Chimeric Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 27 Murine Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 28 Murine Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Vaccines Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 30 Vaccines Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Recombinant Proteins Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 32 Recombinant Proteins Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 33 Regenerative Medicine Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 34 Regenerative Medicine Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 35 Tissue Engineered Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 36 Tissue Engineered Products Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 37 Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 38 Cell Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Gene Therapies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 40 Gene Therapies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 42 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Biologics Market by Application: Market Attractiveness Index
Figure 44 Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 45 Biologics Share Forecast by Application, 2024, 2029, 2034 (%)
Figure 46 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 47 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 48 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 49 Infectious Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Autoimmune Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 51 Autoimmune Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 52 Haematological Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 53 Haematological Disorders Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 54 Cardiovascular Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 55 Cardiovascular Disorders Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 56 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 57 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 58 Biologics Market by Manufacturing Type: Market Attractiveness Index
Figure 59 Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
Figure 60 Biologics Share Forecast by Manufacturing Type, 2024, 2029, 2034 (%)
Figure 61 Outsource Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 62 Outsource Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 63 In-house Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 64 In-house Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 65 Biologics Market by End-users: Market Attractiveness Index
Figure 66 Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 67 Biologics Share Forecast by End-users, 2024, 2029, 2034 (%)
Figure 68 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 69 Hospitals Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 70 Speciality Centres Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 71 Speciality Centres Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 72 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 73 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 74 Biologics Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 75 Biologics Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 76 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %)
Figure 77 North America Biologics Market Attractiveness Index
Figure 78 North America Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 79 North America Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 80 North America Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 81 North America Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 82 North America Biologics Market Share Forecast by Product, 2024 & 2034 (%)
Figure 83 North America Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 84 North America Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 85 North America Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
Figure 86 North America Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
Figure 87 North America Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 88 North America Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 89 U.S. Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 90 Canada Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 91 Europe Biologics Market Attractiveness Index
Figure 92 Europe Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 93 Europe Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 94 Europe Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 95 Europe Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 96 Europe Biologics Market Share Forecast by Product, 2024 & 2034 (%)
Figure 97 Europe Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 98 Europe Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 99 Europe Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
Figure 100 Europe Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
Figure 101 Europe Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 102 Europe Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 103 Germany Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 104 UK Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 105 France Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 106 Italy Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 107 Spain Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 108 Russia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 109 Rest of Europe Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 110 Asia Biologics Market Attractiveness Index
Figure 111 Asia Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 112 Asia Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 113 Asia Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 114 Asia Pacific Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 115 Asia Pacific Biologics Market Share Forecast by Product, 2024 & 2034 (%)
Figure 116 Asia Pacific Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 117 Asia Pacific Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 118 Asia Pacific Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
Figure 119 Asia Pacific Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
Figure 120 Asia Pacific Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 121 Asia Pacific Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 122 Japan Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 123 China Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 124 India Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 125 Australia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 126 South Korea Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 127 Rest of Asia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 128 Latin America Biologics Market Attractiveness Index
Figure 129 Latin America Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 130 Latin America Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 131 Latin America Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 132 Latin America Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 133 Latin America Biologics Market Share Forecast by Product, 2024 & 2034 (%)
Figure 134 Latin America Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 135 Latin America Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 136 Latin America Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
Figure 137 Latin America Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
Figure 138 Latin America Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 139 Latin America Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 140 Brazil Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 141 Mexico Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 142 Argentina Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 143 Rest of Latin America Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 144 MEA Biologics Market Attractiveness Index
Figure 145 MEA Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 146 MEA Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 147 MEA Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 148 MEA Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 149 MEA Biologics Market Share Forecast by Product, 2024 & 2034 (%)
Figure 150 MEA Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 151 MEA Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 152 MEA Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
Figure 153 MEA Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
Figure 154 MEA Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 155 MEA Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 156 GCC Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 157 South Africa Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 158 Rest of MEA Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 159 Biologics Market: Company Share Analysis, 2022
Figure 160 Johnson & Johnson: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 161 Johnson & Johnson: R&D, 2017-2022 (US$ Million, AGR%)
Figure 162 Johnson & Johnson: Regional Market Shares, 2022
Figure 163 Johnson & Johnson: Business Market Shares, 2022
Figure 164 F. Hoffmann-La Roche AG: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 165 F. Hoffmann-La Roche AG: R&D, 2017-2022 (US$ Million, AGR%)
Figure 166 F. Hoffmann-La Roche AG: Regional Market Shares, 2022
Figure 167 F. Hoffmann-La Roche AG: Business Market Shares, 2022
Figure 168 Amgen Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 169 Amgen Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 170 Amgen Inc.: Regional Market Shares, 2022
Figure 171 Amgen Inc.: Business Market Shares, 2022
Figure 172 AbbVie Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 173 AbbVie Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 174 AbbVie Inc.: Regional Market Shares, 2022
Figure 175 Novo Nordisk A/S: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 176 Novo Nordisk A/S: R&D, 2017-2022 (US$ Million, AGR%)
Figure 177 Novo Nordisk A/S: Regional Market Shares, 2022
Figure 178 Novo Nordisk A/S: Business Market Shares, 2022
Figure 179 Eli Lilly and Company: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 180 Eli Lilly and Company: R&D, 2017-2022 (US$ Million, AGR%)
Figure 181 Eli Lilly and Company: Regional Market Shares, 2022
Figure 182 Eli Lilly and Company: Business Market Shares, 2022
Figure 183 Bristol-Myers Squibb Company: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 184 Bristol-Myers Squibb Company: R&D, 2017-2022 (US$ Million, AGR%)
Figure 185 Bristol-Myers Squibb Company: Regional Market Shares, 2022
Figure 186 Bristol-Myers Squibb Company: Business Market Shares, 2022
Figure 187 Merck & Co.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 188 Merck & Co.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 189 Merck & Co.: Regional Market Shares, 2022
Figure 190 Merck & Co.: Business Market Shares, 2022
Figure 191 AstraZeneca plc: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 192 AstraZeneca plc: R&D, 2017-2022 (US$ Million, AGR%)
Figure 193 AstraZeneca plc: Regional Market Shares, 2022
Figure 194 AstraZeneca plc: Business Market Shares, 2022
Figure 195 Sanofi: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 196 Sanofi: R&D, 2017-2022 (US$ Million, AGR%)
Figure 197 Sanofi: Regional Market Shares, 2022
Figure 198 Sanofi: Business Market Shares, 2022
Figure 199 Pfizer Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 200 Pfizer Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 201 Pfizer Inc.: Regional Market Shares, 2023
Figure 202 Pfizer Inc.: Business Market Shares, 2022
Figure 203 Regeneron Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 204 Regeneron Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 205 Regeneron Pharmaceuticals, Inc.: Business Market Shares, 2022
Figure 206 Gilead Sciences, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 207 Gilead Sciences, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 208 Gilead Sciences, Inc.: Regional Market Shares, 2022
Figure 209 Gilead Sciences, Inc: Business Market Shares, 2022
Figure 210 Celltrion, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 211 Biogen Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 212 Biogen Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 213 Biogen Inc.: Regional Market Shares, 2022
ページTOPに戻る
本レポートと同じKEY WORD（oncology）の最新刊レポート
よくあるご質問
Visiongain社はどのような調査会社ですか?
英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る
調査レポートの納品までの日数はどの程度ですか?
在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。
注文の手続きはどのようになっていますか?
1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。
お支払方法の方法はどのようになっていますか?
納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。
データリソース社はどのような会社ですか?
当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。
|
|
